Recombinant human erythropoietin does not regulate the expression of endothelin-1 and constitutive nitric oxide synthase in vascular endothelial cells.
Erythropoietin (rHuEPO)-induced hypertension represents a clinical problem in hemodialysis units. However, the underlying molecular mechanisms of this side effect are still unclear. In order to assess the potential participation of the endothelial-derived vasoactive factors, nitric oxide and endothelin-1, bovine aortic endothelial cells were incubated in the presence of rHuEPO. The latter (0.1-10 U/ml, 1-24 h) did not modify the synthesis of nitric oxide and endothelin-1 or the expression of nitric oxide synthase and pre-pro-endothelin-1 mRNAs. These results suggest that endothelial-derived vasoactive factors are not a key component in the hypertensive response observed in certain patients after the administration of rHuEPO.
López Ongil
S L
SL
Department of Physiology, Alcalá de Henares University, Madrid, Spain.
Saura
M
M
Lamas
S
S
Rodriguez Puyol
M
M
Rodriguez Puyol
D
D
D000818:Animals; D001013:Aorta, Thoracic; D002417:Cattle; D002478:Cells, Cultured; D006152:Cyclic GMP / Q000096:biosynthesis; D016232:Endothelins / Q000235:genetics*; D004730:Endothelium, Vascular / Q000378:metabolism*; D004921:Erythropoietin / Q000494:pharmacology*; D005786:Gene Expression Regulation / Q000187:drug effects*; D006801:Humans; D007700:Kinetics; D019001:Nitric Oxide Synthase / Q000235:genetics*; D012333:RNA, Messenger / Q000378:metabolism; D011994:Recombinant Proteins / Q000494:pharmacology
D016232:Endothelins; D012333:RNA, Messenger; D011994:Recombinant Proteins; D004921:Erythropoietin; D019001:Nitric Oxide Synthase; D006152:Cyclic GMP